Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 09, 2023

Olaparib Plus Abiraterone vs Placebo Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
Lancet Oncol 2023 Sep 12;[EPub Ahead of Print], F Saad, NW Clarke, M Oya, N Shore, G Procopio, JD Guedes, C Arslan, N Mehra, F Parnis, E Brown, F Schlürmann, JY Joung, M Sugimoto, O Sartor, YZ Liu, C Poehlein, L Barker, PM Del Rosario, AJ Armstrong

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.


Further Reading